Icecure Medical

ICCM · NASDAQ

$1.01+$0.01 (+1.00%)TodayMarket closed · Oct 23, 7:27 PM ET

Prev close $1.00

ICCM analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $23.12 (+2189.1% upside)

Low: $10.10
Now: $1.01
High: $31.50

Upgrades and downgrades

The latest rating actions, newest first

ICCM analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	May 14, 2026	Maintains	Buy	$3.00 → $1.00	26%

The case for and against

Updated Nov 19, 2025

Bull case

Icecure Medical Ltd is positioned for positively impacting its topline sales in the first half of 2026, largely due to anticipated FDA marketing authorization for its ProSense cryoablation system for breast cancer in 2025. The successful De Novo clearance and encouraging results from the ICE3 trial underscore the efficacy of their liquid nitrogen-based technology as a minimally invasive treatment alternative, which may further enhance market adoption. Additionally, a narrower net loss of $3.6 million per share, compared to earlier estimates, reflects improved financial stability and operational efficiency that could support future growth prospects.

Bear case

IceCure Medical reported a revenue of $725K for 1Q25, reflecting a 2% year-over-year decline, which aligns closely with projections but indicates stagnation in sales. The company faces challenges in achieving commercial success for its cryoablation systems due to limited market size and increasing competition, particularly highlighted by weak performance in the Asian market. Additionally, the presence of dilution risk further complicates the financial outlook, raising concerns among investors about the sustainability and growth potential of the company's revenue streams.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.